SHP 654

Drug Profile

SHP 654

Alternative Names: BAX 888; FVIII gene therapy; SHP654

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxalta
  • Developer Shire
  • Class Gene therapies
  • Mechanism of Action Blood coagulation factor replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haemophilia A

Most Recent Events

  • 15 Feb 2018 Phase-I/II clinical trials in Haemophilia A in USA (IV) (NCT03370172)
  • 25 Oct 2017 Shire plans a phase I/II trial for Haemophilia A worldwide by end of 2017 (NCT03370172)
  • 25 Oct 2017 SHP 654 receives Orphan Drug status for Haemophilia A in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top